AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35377929 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listened to music in the waiting room until immediately before IVS)
Number of subjects: 60
Study 35377929 — intervention group
Group type: COMPARATOR
Intervention: Nonmusic (did not listen to music)
Number of subjects: 60
Study 34423347 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D radiomics model
Number of subjects: 146
Study 34423347 — intervention group
Group type: COMPARATOR
Intervention: Qualitative analysis (mrEMVI and sphincter invasion)
Number of subjects: 146
Study 34423347 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics models (all three models)
Number of subjects: 146
Study 32957336 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Number of subjects: 254
Study 32957336 — intervention group
Group type: COMPARATOR
Intervention: 7 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Number of subjects: 254
Study 35148357 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 12 weeks
Number of subjects: 13
Study 35148357 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 13
Study 35148357 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 13
Study 35148357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 33027078 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (postprandial distress syndrome)
Number of subjects: 4562
Study 33027078 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (epigastric pain syndrome)
Number of subjects: 4562
Study 33027078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease
Number of subjects: 4562
Study 36324245 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-7246 300 μg
Number of subjects: 388
Study 36324245 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-7246 600 μg
Number of subjects: 388
Study 36324245 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-7246 1200 μg
Number of subjects: 388
Study 36324245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 33632268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric integrative manual therapy (PIMT) combined with caregiver education program
Number of subjects: 34
Study 33632268 — intervention group
Group type: COMPARATOR
Intervention: Caregiver education program only
Number of subjects: 34
Study 33632268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 35313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent chest X-ray
Number of subjects: 11
Study 35313926 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 11
Study 32529753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 32529753 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0
Study 35043692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (≥180 mg/dL)
Number of subjects: 4878
Study 35043692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 4878
Study 35043692 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (<180 mg/dL)
Number of subjects: 4878
Study 34558624 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma 25-hydroxyvitamin D (25(OH)D) levels in normal fasting blood glucose (NFG) group
Number of subjects: 591
Study 34558624 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma 25-hydroxyvitamin D (25(OH)D) levels in impaired fasting glucose (IFG) group
Number of subjects: 591
Study 34558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes with low plasma 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 591
Study 34558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group of IFG and diabetes
Number of subjects: 591
Study 34558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 591
Study 33249498 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) study cigarettes tapered every three weeks to a final VLNC (0.2 mg/cigarette) for six weeks
Number of subjects: 245
Study 33249498 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) study cigarettes
Number of subjects: 245
Study 33249498 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant VLNC smokers
Number of subjects: 245
Study 33249498 — intervention group
Group type: COMPARATOR
Intervention: Usual nicotine content (UNC) study cigarettes (11.6 mg/cigarette)
Number of subjects: 245
Study 32236521 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days)
Number of subjects: 19
Study 32236521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34610387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 658
Study 34610387 — intervention group
Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy (3DCRT)
Number of subjects: 658
Study 34421675 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Ayahuasca
Number of subjects: 30
Study 34421675 — intervention group
Group type: COMPARATOR
Intervention: Ayahuasca
Number of subjects: 30
Study 34421675 — intervention group
Group type: COMPARATOR
Intervention: Cannabidiol (CBD) + Ayahuasca
Number of subjects: 30
Study 33667037 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal gender ideology
Number of subjects: 342
Study 33667037 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal men
Number of subjects: 342
Study 35692201 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning and back propagation (BP) neural network model for predicting acute exacerbation of COPD
Number of subjects: 1326
Study 35692201 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning and BP neural network model for predicting acute exacerbation of COPD
Number of subjects: 1326
Study 35291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than baseline preoperative blood pressure (MAP allowed to increase up to 20% higher than baseline MAP by inducing pneumoperitoneum)
Number of subjects: 72
Study 35291408 — intervention group
Group type: COMPARATOR
Intervention: Normal to low blood pressure (MAP deliberately controlled at a tight limit from normal baseline MAP values to 20% less than baseline by titrating TNG infusion)
Number of subjects: 72
Study 35039498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (placebo-controlled)
Number of subjects: 0
Study 35404188 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized basket trial design with family wise error rate control at 0.025k
Number of subjects: 0
Study 35404188 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized confirmatory basket trials
Number of subjects: 0
Study 33927114 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength, Power, and Hypertrophy (SPH) group
Number of subjects: 35
Study 33927114 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength, Power, and Functional (SP + Func) group
Number of subjects: 35
Study 32302261 — intervention group
Group type: EXPERIMENTAL
Intervention: Child disclosure
Number of subjects: 217
Study 32302261 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher disclosure
Number of subjects: 217
Study 32302261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother disclosure
Number of subjects: 217
Study 32302261 — intervention group
Group type: COMPARATOR
Intervention: Control (no stuttering disclosure)
Number of subjects: 217
Study 32116252 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural Learning Skill (PLSC) task
Number of subjects: 26
Study 32116252 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-motor reaction times
Number of subjects: 26
Study 36006858 — intervention group
Group type: EXPERIMENTAL
Intervention: The Real Cost vaping prevention ads
Number of subjects: 623
Study 36006858 — intervention group
Group type: EXPERIMENTAL
Intervention: The Real Cost smoking prevention ads
Number of subjects: 623
Study 34380790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT) (one hour on and two hours off)
Number of subjects: 174
Study 34380790 — intervention group
Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT) (with minimum interruptions for feeding)
Number of subjects: 174
Study 34380790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT)
Number of subjects: 174
Study 34380790 — intervention group
Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT)
Number of subjects: 174
Study 32966585 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn)
Number of subjects: 0
Study 32966585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35428679 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 3623
Study 35428679 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (in prespecified subsample)
Number of subjects: 3623
Study 35428679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 3623
Study 32087031 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried German chamomile tea capsules
Number of subjects: 0
Study 32087031 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing lactose
Number of subjects: 0
Study 34111992 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Number of subjects: 50
Study 34111992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Number of subjects: 50
Study 34111992 — intervention group
Group type: COMPARATOR
Intervention: Comparison between landmark-guided and ultrasonography-guided injections
Number of subjects: 50
Study 32482541 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, Bortezomib, and Dexamethasone (D-Vd)
Number of subjects: 498
Study 33164580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette (59 mg/mL)
Number of subjects: 15
Study 33164580 — intervention group
Group type: COMPARATOR
Intervention: Placebo e‐cigarette (0 mg/mL)
Number of subjects: 15
Study 33074857 — intervention group
Group type: EXPERIMENTAL
Intervention: Defer ART until the WHO criteria were met
Number of subjects: 477
Study 33074857 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma biomarkers (sVCAM-1, sCD14)
Number of subjects: 477
Study 36270493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in addition to aspirin
Number of subjects: 10156
Study 36270493 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to aspirin
Number of subjects: 10156
Study 36270493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in addition to aspirin (THEMIS-PCI substudy)
Number of subjects: 10156
Study 33962511 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including rib raising and suboccipital release in addition to standard asthma care.
Number of subjects: 58
Study 33962511 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group).
Number of subjects: 58
Study 33077567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant therapy (Curosurf, Chiesi Pharmaceuticals, Italy)
Number of subjects: 0
Study 33077567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 0
Study 33077567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant therapy (Curosurf)
Number of subjects: 0
Study 34410414 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy (PFT-guided)
Number of subjects: 2285
Study 34410414 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet treatment
Number of subjects: 2285
Study 33750034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice daily for 14 weeks
Number of subjects: 32
Study 33750034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33750034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 32
Study 33750034 — intervention group
Group type: COMPARATOR
Intervention: Both MMF and Placebo
Number of subjects: 32
Study 35567420 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product of rosuvastatin 10 mg
Number of subjects: 28
Study 35567420 — intervention group
Group type: COMPARATOR
Intervention: Reference product of rosuvastatin 10 mg
Number of subjects: 28
Study 35567420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 28
Study 35567420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rosuvastatin 10 mg
Number of subjects: 28
Study 34340936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial preparation with GnRH agonist pre-treatment (group A)
Number of subjects: 188
Study 34340936 — intervention group
Group type: COMPARATOR
Intervention: Endometrial preparation without GnRH agonist pre-treatment (group B)
Number of subjects: 188
Study 35613387 — intervention group
Group type: EXPERIMENTAL
Intervention: HH+CO2
Number of subjects: 10
Study 35613387 — intervention group
Group type: COMPARATOR
Intervention: HH
Number of subjects: 10
Study 32376946 — intervention group
Group type: EXPERIMENTAL
Intervention: 333 Hz tACS
Number of subjects: 0
Study 32376946 — intervention group
Group type: EXPERIMENTAL
Intervention: 667 Hz tACS
Number of subjects: 0
Study 32376946 — intervention group
Group type: COMPARATOR
Intervention: Sham-tACS
Number of subjects: 0
Study 36182028 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1200 mg TID
Number of subjects: 98
Study 36182028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 32839468 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 46
Study 32839468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 35577483 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program with situational simulation video (2 weeks duration)
Number of subjects: 100
Study 35577483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 100
Study 33569560 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multidomain intervention group (MIG)
Number of subjects: 120
Study 33569560 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study 32961273 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 29
Study 32961273 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study 35268481 — intervention group
Group type: EXPERIMENTAL
Intervention: Subetta therapy for 12 weeks
Number of subjects: 0
Study 35268481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35273943 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive risk model for predicting cancer-specific survival (CSS) in elderly patients with chRCC
Number of subjects: 3522
Study 35273943 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA) model
Number of subjects: 3522
Study 33548429 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for detecting AAAs
Number of subjects: 32778
Study 33548429 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for confirming absence of AAAs
Number of subjects: 32778
Study 33548429 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for identifying maximal aortic diameter
Number of subjects: 32778
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 30 mg
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 60 mg
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 120 mg
Number of subjects: 0
Study 34534272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 30 mg (rivaroxaban)
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 60 mg (rivaroxaban)
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 120 mg (rivaroxaban)
Number of subjects: 0
Study 34534272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag 180 mg (rivaroxaban)
Number of subjects: 0
Study 34534272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rivaroxaban)
Number of subjects: 0
Study 34694215 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted smoking cessation treatment
Number of subjects: 169
Study 32268336 — intervention group
Group type: EXPERIMENTAL
Intervention: ADQI consensus conference reports
Number of subjects: 34
Study 32268336 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 34
Study 35292005 — intervention group
Group type: EXPERIMENTAL
Intervention: AktiFAME strategy (Active access, counseling, and case management)
Number of subjects: 9000
Study 35292005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9000
Study 35292005 — intervention group
Group type: EXPERIMENTAL
Intervention: AktiFAME strategy
Number of subjects: 9000
Study 33822433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical syntactic structure‐building Grammar (HG)
Number of subjects: 36
Study 33822433 — intervention group
Group type: COMPARATOR
Intervention: Nested associating Grammar (NG)
Number of subjects: 36
Study 36307353 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 0
Study 36307353 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 0
Study 33517738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% CHX (alcoholic chlorhexidine)
Number of subjects: 116
Study 33517738 — intervention group
Group type: COMPARATOR
Intervention: Dermol (DML) 500 emollient
Number of subjects: 116
Study 33517738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 116
Study 35941622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation sessions (twice weekly for six weeks) consisting of supervised stretching, aerobic and strengthening exercises, and patient education.
Number of subjects: 54
Study 35941622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 54
Study 34397727 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.0 ng/mL
Number of subjects: 80
Study 34397727 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at 2.0 ng/mL
Number of subjects: 80
Study 32925628 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective labor induction at 39 weeks of gestation
Number of subjects: 5007
Study 32925628 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 5007
Study 33284965 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g/d)
Number of subjects: 23
Study 33284965 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 23
Study 33284965 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 23
Study 32562884 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCNS‐SC transplantation (0.25 × 10^6 or 1.0 × 10^6 HuCNS‐SCs infused directly into the subretinal space)
Number of subjects: 15
Study 32562884 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCNS‐SC transplantation
Number of subjects: 15
Study 33026449 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus icotinib (125 mg 3 times a day)
Number of subjects: 127
Study 33026449 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 127
Study 33026449 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus icotinib
Number of subjects: 127
Study 35831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eccentric/fast concentric phase group (S/F; 4 s and 1 s)
Number of subjects: 20
Study 35831629 — intervention group
Group type: COMPARATOR
Intervention: Fast eccentric/fast concentric phase group (F/F; 1 s both phases)
Number of subjects: 20
Study 35831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (F/F and S/F)
Number of subjects: 20
Study 32737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in multiple neonatal clinical trials
Number of subjects: 17
Study 32737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risks and benefits of each individual study
Number of subjects: 17
Study 32737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental autonomy in decision-making
Number of subjects: 17
Study 32737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of parental feelings
Number of subjects: 17
Study 32737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacity to remember details of multiple studies
Number of subjects: 17
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume same-day PEG (15 mg bisacodyl the day before, 2 L the morning of the procedure)
Number of subjects: 1750
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume split-dose PEG (2 L + 2 L)
Number of subjects: 1750
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume split-dose PEG (15 mg bisacodyl the day before, 1 L + 1 L)
Number of subjects: 1750
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume same-day PEG
Number of subjects: 1750
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume split-dose PEG
Number of subjects: 1750
Study 32740079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume split-dose PEG
Number of subjects: 1750
Study 36410811 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination available every day at health facility contact
Number of subjects: 23